TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M

TELA Bio, Inc.

Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.
Total consideration at least $8M and up to $12M from MiMedx for the wound care product.
NIVIS is an absorbent collagen matrix indicated for wound management and minor bleeding.
TELA to focus on hernia repair and reconstructive surgery products, including new LIQUIFIX and OviTex configurations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.